The global Chinese hamster ovary (CHO) cells market is projected to register a CAGR of 8.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation
Global Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), application(Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest Of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest Of Asia-Pacific, Brazil, Argentina, Rest Of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain, and Rest of Middle East And Africa) - Industry Trends And Forecast to 2030
Overview of Global Chinese Hamster Ovary (CHO) Cells Market Dynamics
- Drivers
- Rising use of CHO cells in the genetic study
- Growing demand for biopharmaceuticals
- Restraint
- Rising number of applications of CHO cells
- Opportunity
- Rising number of applications of CHO cells
Market Players
Some major companies operating in the global Chinese Hamster Ovary (CHO) Cells market are:
- Thermo Fisher Scientific Inc. (U.S.)
- AcceGen (U.S.)
- RayBiotech Life, Inc. (U.S.)
- CLS Cell Lines Service GmbH (Germany)
- BPS Bioscience, Inc. (U.S.)
- GenTarget Inc. (U.S.)
- Merck KGaA (Germany)
- Promega Corporation (U.S.)
- Abeomics (U.S.)
- Applied Biological Materials Inc. (abm) (Canada)
- ATCC (U.S.)
- Sartorius AG (Germany)
- Lonza (Switzerland)
- Horizon Discovery Ltd. (U.K.)
- Cytiva (U.S.)
- GTP Bioways (France)
- Curia Global, Inc. (U.S.)
TABLE OF CONTENTS
1 INTRODUCTION 48
- 1.1 OBJECTIVES OF THE STUDY 48
- 1.2 MARKET DEFINITION 48
- 1.3 OVERVIEW OF THE GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET 48
- 1.4 LIMITATIONS 50
- 1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
- 2.1 MARKETS COVERED 53
- 2.2 GEOGRAPHICAL SCOPE 54
- 2.3 YEARS CONSIDERED FOR THE STUDY 55
- 2.4 CURRENCY AND PRICING 55
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
- 2.6 MULTIVARIATE MODELLING 59
- 2.7 GLOBAL CHINESE HAMSTER OVARY (CHO) CELL, BY TYPE, LIFELINE CURVE 59
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
- 2.9 DBMR MARKET POSITION GRID 61
- 2.10 MARKET APPLICATION COVERAGE GRID 62
- 2.11 VENDOR SHARE ANALYSIS 63
- 2.12 SECONDARY SOURCES 64
- 2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHTS 68
- 4.1 PESTEL ANALYSIS 71
- 4.2 PORTER'S FIVE FORCES 72
5 GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, REGULATIONS 73
6 MARKET OVERVIEW 75
- 6.1 DRIVERS 77
- 6.1.1 RISING USE OF CHO CELLS IN THE GENETIC STUDY 77
- 6.1.2 GROWING DEMAND FOR BIOPHARMACEUTICALS 78
- 6.1.3 RISING INVESTMENTS IN BIOTECHNOLOGY R&D 78
- 6.1.4 RISING DEMAND FOR MONOCLONAL ANTIBODIES 80
- 6.2 RESTRAINTS 81
- 6.2.1 HIGH-COST OF CHO CELL-BASED PRODUCTION 81
- 6.2.2 STRICT REGULATORY REQUIREMENTS FOR CHO CELL-BASED PRODUCTION 81
- 6.3 OPPORTUNITIES 82
- 6.3.1 CONTINUOUS DEVELOPMENT OF CELL CULTURE TECHNOLOGIES 82
- 6.3.2 RISING NUMBER OF APPLICATIONS OF CHO CELLS 84
- 6.4 CHALLENGES 85
- 6.4.1 TIME-CONSUMING AND INCONSISTENCY IN CHO CELL LINE DEVELOPMENT PROCESS 85
- 6.4.2 CONTAMINATION RISK OF CHO CELL CULTURES 86
7 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE 87
- 7.1 OVERVIEW 88
- 7.2 SERVICES 89
- 7.3 PRODUCT 90
- 7.3.1 CHO-DXB11 90
- 7.3.2 CHO-K1 91
- 7.3.2.1 CHO-K1 ATCC 91
- 7.3.2.2 CHO-K1 ECACC 91
- 7.3.2.3 OTHERS 91
- 7.3.3 CHO-DG44 91
- 7.3.4 CHO-S 91
- 7.3.5 OTHERS 91
8 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM 92
- 8.1 OVERVIEW 93
- 8.2 METABOLIC SELECTION SYSTEM 94
- 8.3 ANTIBIOTIC SELECTION SYSTEM 95
- 8.4 OTHERS 95
9 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION 96
- 9.1 OVERVIEW 97
- 9.2 BIOLOGICS 98
- 9.2.1 MONOCLONAL ANTIBODIES 99
- 9.2.2 ENZYMES 99
- 9.2.3 CYTOKINES 99
- 9.2.4 CLOTTING FACTORS 99
- 9.2.5 HORMONES 99
- 9.2.6 FC-FUSION PROTIEN 99
- 9.2.7 OTHERS 100
- 9.3 MEDICAL RESEARCH 100
10 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER 101
- 10.1 OVERVIEW 102
- 10.2 BIOPHARMACEUTICAL COMPANIES 103
- 10.2.1 MEDIUM 104
- 10.2.2 SMALL 104
- 10.3 BIOTECHNOLOGY COMPANIES 104
- 10.3.1 MEDIUM 105
- 10.3.2 SMALL 105
- 10.4 CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS 105
- 10.4.1 MEDIUM 106
- 10.4.2 SMALL 106
- 10.5 CLINICAL RESEARCH ORGANIZATIONS 106
- 10.5.1 MEDIUM 107
- 10.5.2 SMALL 107
- 10.6 ACADEMIC INSTITUTES AND RESEARCH ORGANIZATIONS 107
- 10.7 OTHERS 108
11 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL 109
- 11.1 OVERVIEW 110
- 11.2 DIRECT TENDERS 111
- 11.3 RETAIL SALES 112
- 11.4 OTHERS 112
12 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY REGION 113
- 12.1 OVERVIEW 114
- 12.2 NORTH AMERICA 117
- 12.3 EUROPE 137
- 12.4 ASIA-PACIFIC 218
- 12.5 SOUTH AMERICA 289
- 12.6 MIDDLE EAST AND AFRICA 302
13 GLOBAL CHINESE HAMSTER OVARY (CHO) CELLS MARKET, COMPANY LANDSCAPE 341
- 13.1 COMPANY SHARE ANALYSIS: GLOBAL 341
- 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 342
- 13.3 COMPANY SHARE ANALYSIS: EUROPE 343
- 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 344
14 SWOT ANALYSIS 345
15 COMPANY PROFILE 346
- 15.1 LONZA 346
- 15.1.1 COMPANY SNAPSHOT 346
- 15.1.2 REVENUE ANALYSIS 346
- 15.1.3 COMPANY SHARE ANALYSIS 347
- 15.1.4 PRODUCT PORTFOLIO 347
- 15.1.5 RECENT DEVELOPMENT 347
- 15.2 SARTORIUS AG 348
- 15.2.1 COMPANY SNAPSHOT 348
- 15.2.2 REVENUE ANALYSIS 348
- 15.2.3 COMPANY SHARE ANALYSIS 349
- 15.2.4 PRODUCT PORTFOLIO 349
- 15.2.5 RECENT DEVELOPMENT 349
- 15.3 MERCK KGAA 350
- 15.3.1 COMPANY SNAPSHOT 350
- 15.3.2 REVENUE ANALYSIS 350
- 15.3.3 COMPANY SHARE ANALYSIS 351
- 15.3.4 PRODUCT PORTFOLIO 351
- 15.3.5 RECENT DEVELOPMENT 351
- 15.4 CYTIVA 352
- 15.4.1 COMPANY SNAPSHOT 352
- 15.4.2 COMPANY SHARE ANALYSIS 352
- 15.4.3 PRODUCT PORTFOLIO 352
- 15.4.4 RECENT DEVELOPMENT 352
- 15.5 THERMO FISHER SCIENTIFIC INC. 353
- 15.5.1 COMPANY SNAPSHOT 353
- 15.5.2 REVENUE ANALYSIS 353
- 15.5.3 COMPANY SHARE ANALYSIS 354
- 15.5.4 PRODUCT PORTFOLIO 354
- 15.5.5 RECENT DEVELOPMENT 354
- 15.6 ABEOMICS 355
- 15.6.1 COMPANY SNAPSHOT 355
- 15.6.2 PRODUCT PORTFOLIO 355
- 15.6.3 RECENT DEVELOPMENT 355
- 15.7 ACCEGEN 356
- 15.7.1 COMPANY SNAPSHOT 356
- 15.7.2 PRODUCT PORTFOLIO 356
- 15.7.3 RECENT DEVELOPMENT 356
- 15.8 APPLIED BIOLOGICAL MATERIALS INC. (ABM) 357
- 15.8.1 COMPANY SNAPSHOT 357
- 15.8.2 PRODUCT PORTFOLIO 357
- 15.8.3 RECENT DEVELOPMENT 357
- 15.9 ATCC 358
- 15.9.1 COMPANY SNAPSHOT 358
- 15.9.2 PRODUCT PORTFOLIO 358
- 15.9.3 RECENT DEVELOPMENT 358
- 15.10 BPS BIOSCIENCE, INC. 359
- 15.10.1 COMPANY SNAPSHOT 359
- 15.10.2 PRODUCT PORTFOLIO 359
- 15.10.3 RECENT DEVELOPMENT 359
- 15.11 CLS CELL LINES SERVICE GMBH 360
- 15.11.1 COMPANY SNAPSHOT 360
- 15.11.2 PRODUCT PORTFOLIO 360
- 15.11.3 RECENT DEVELOPMENT 360
- 15.12 CURIA GLOBAL, INC. 361
- 15.12.1 COMPANY SNAPSHOT 361
- 15.12.2 PRODUCT PORTFOLIO 361
- 15.12.3 RECENT DEVELOPMENT 361
- 15.13 GENTARGET INC. 362
- 15.13.1 COMPANY SNAPSHOT 362
- 15.13.2 PRODUCT PORTFOLIO 362
- 15.13.3 RECENT DEVELOPMENT 362
- 15.14 GTP BIOWAYS 363
- 15.14.1 COMPANY SNAPSHOT 363
- 15.14.2 PRODUCT PORTFOLIO 363
- 15.14.3 RECENT DEVELOPMENT 363
- 15.15 HORIZON DISCOVERY LTD. 364
- 15.15.1 COMPANY SNAPSHOT 364
- 15.15.2 PRODUCT PORTFOLIO 364
- 15.15.3 RECENT DEVELOPMENT 364
- 15.16 PROMEGA CORPORATION 365
- 15.16.1 COMPANY SNAPSHOT 365
- 15.16.2 PRODUCT PORTFOLIO 365
- 15.16.3 RECENT DEVELOPMENT 365
- 15.17 RAYBIOTECH LIFE, INC. 366
- 15.17.1 COMPANY SNAPSHOT 366
- 15.17.2 PRODUCT PORTFOLIO 366
- 15.17.3 RECENT DEVELOPMENT 366
16 QUESTIONNAIRE 367
17 RELATED REPORTS 371